Literature DB >> 385502

Role of Escherichia coli K capsular antigens during complement activation, C3 fixation, and opsonization.

W C Van Dijk, H A Verbrugh, M E van der Tol, R Peters, J Verhoef.   

Abstract

Escherichia coli strains with K capsular polysaccharides are relatively resistant to phagocytosis by polymorphonuclear leukocytes, in contrast to E. coli strains without K antigens. This inhibition of phagocytosis is related to an impaired recognition of the K+ strains by the phagocytes due to ineffective opsonization. All five strains without K antigens were readily phagocytized after opsonization in 5% normal serum, compared with no uptake of the K+ strains. Evidence is presented that the decreased opsonization of the K+ strains in normal serum is caused by a low rate of complement activation of the strains, with subsequent absence of C3b fixation or C3d fixation or both to the cell wall of the bacteria. After removal of the K+ antigens by heating of a K+ E. coli strain, the strain was able to activate complement, to bind C3b or C3d or both, and to become opsonized. Complement was then activated via the classical and alternative pathways, which was comparable to the complement consumption by K- E. coli.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 385502      PMCID: PMC414488          DOI: 10.1128/iai.25.2.603-609.1979

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

1.  Opsonic requirements for phagocytosis of Streptococcus pneumoniae types VI, XVIII, XXIII, and XXV.

Authors:  G S Giebink; J Verhoef; P K Peterson; P G Quie
Journal:  Infect Immun       Date:  1977-11       Impact factor: 3.441

2.  Restricted complement activation by Escherichia coli with the K-1 capsular serotype: a possible role in pathogenicity.

Authors:  P Stevens; S N Huang; W D Welch; L S Young
Journal:  J Immunol       Date:  1978-12       Impact factor: 5.422

3.  Opsonic requirements for staphylococcal phagocytosis. Heterogeneity among strains.

Authors:  J Verhoef; P Peterson; Y Kim; L D Sabath; P G Quie
Journal:  Immunology       Date:  1977-08       Impact factor: 7.397

4.  Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (LPS).

Authors:  D C Morrison; L F Kline
Journal:  J Immunol       Date:  1977-01       Impact factor: 5.422

5.  Virulence of Escherichia coli K1 in adults.

Authors:  J Pitt
Journal:  J Infect Dis       Date:  1979-01       Impact factor: 5.226

6.  Escherichia coli K antigen in relation to serum-induced lysis and phagocytosis.

Authors:  W C Van Dijk; H A Verbrugh; R Peters; M E Van Der Tol; P K Peterson; J Verhoef
Journal:  J Med Microbiol       Date:  1979-02       Impact factor: 2.472

7.  Quantitative fluorescent immunoassay of antibodies to, and surface antigens of, Actinomyces viscosus.

Authors:  T P Gillis; J J Thompson
Journal:  J Clin Microbiol       Date:  1978-02       Impact factor: 5.948

8.  Activation of complement by opportunist pathogens and chemotypes of Salmonella minnesota.

Authors:  A B Bjornson; H S Bjornson
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

9.  Phagocytosis and killing of staphylococci by human polymorphonuclear and mononuclear leucocytes.

Authors:  H A Verbrugh; R Peters; P K Peterson; J Verhoef
Journal:  J Clin Pathol       Date:  1978-06       Impact factor: 3.411

10.  Protective capacity of antibodies against Escherichia coli and K antigens.

Authors:  B Kaijser; S Ahlstedt
Journal:  Infect Immun       Date:  1977-08       Impact factor: 3.441

View more
  25 in total

Review 1.  Target recognition failure by the nonspecific defense system: surface constituents of pathogens interfere with the alternative pathway of complement activation.

Authors:  R D Horstmann
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

2.  The Vi capsular polysaccharide prevents complement receptor 3-mediated clearance of Salmonella enterica serotype Typhi.

Authors:  R Paul Wilson; Sebastian E Winter; Alanna M Spees; Maria G Winter; Jessalyn H Nishimori; Jesus F Sanchez; Sean-Paul Nuccio; Robert W Crawford; Çagla Tükel; Andreas J Bäumler
Journal:  Infect Immun       Date:  2010-11-22       Impact factor: 3.441

3.  Enhanced phagocytosis of encapsulated Escherichia coli strains after exposure to sub-MICs of antibiotics is correlated to changes of the bacterial cell surface.

Authors:  G Raponi; N Keller; B P Overbeek; M Rozenberg-Arska; K P van Kessel; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

Review 4.  Modulation of phagocytic cell function.

Authors:  P A Henricks; J Verhoef; F P Nijkamp
Journal:  Vet Res Commun       Date:  1986-05       Impact factor: 2.459

5.  Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H.

Authors:  R D Horstmann; H J Sievertsen; J Knobloch; V A Fischetti
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

Review 6.  Complement resistance in microbes.

Authors:  M C Moffitt; M M Frank
Journal:  Springer Semin Immunopathol       Date:  1994

7.  Opsonization of various capsular (K) E. coli by the alternative complement pathway.

Authors:  P Stevens; L S Young; S Adamu
Journal:  Immunology       Date:  1983-11       Impact factor: 7.397

8.  Definition of a bacterial virulence factor: sialylation of the group B streptococcal capsule.

Authors:  M R Wessels; C E Rubens; V J Benedí; D L Kasper
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

9.  Inhibition of phagocytosis and chemiluminescence in human leukocytes by a lipid soluble factor in normal tissues.

Authors:  T S Huang; R E Hurd; I J Chopra; P Stevens; D H Solomon; L S Young
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

10.  Antibodies raised against rough mutants of Escherichia coli and Salmonella strains are opsonic only in the presence of complement.

Authors:  R W Vreede; J H Marcelis; J Verhoef
Journal:  Infect Immun       Date:  1986-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.